知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

80 条记录 (耗时 0.05 秒)

    Topical synergistic microbicide
    5.
    发明申请
    Topical synergistic microbicide 审中-公开
    局部协同杀微生物剂

    公开(公告)号：US20030176483A1

    公开(公告)日：2003-09-18

    申请号：US10096672

    申请日：2002-03-13

    发明人： Gerald N. Kern

    IPC分类号： A61K031/4178 ,  A61K031/275 ,  A61K031/24 ,  A61K031/195 ,  A61K031/10

    CPC分类号： A61K47/20 ,  A61K9/0014 ,  A61K45/06

    摘要： Application of topical synergistic microbicide composition(s) of high practical utility both as a treatment and/or prevention against HSV Type 1 and/or Type 2 and related diseases and secondary opportunist disease causing agents, while reducing the inflammation, prolonged healing times and reduce scaring.

    摘要翻译： 应用具有高实用效用的局部协同杀微生物剂组合物作为治疗和/或预防HSV 1型和/或2型及相关疾病和次级机会性疾病引发剂，同时减少炎症，延长愈合时间和减少 害怕

    Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
    7.
    发明申请
    Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma 审中-公开
    抑制SRC激酶家族通路作为治疗HBV感染和肝细胞癌的方法

    公开(公告)号：US20020045191A1

    公开(公告)日：2002-04-18

    申请号：US09955006

    申请日：2001-09-17

    发明人： Robert J. Schneider ,  Nicola Klein

    IPC分类号： A61K048/00 ,  A61K038/17 ,  A61K031/519 ,  A61K031/277 ,  A01N037/34 ,  A61K031/275 ,  A01N043/04 ,  A61K031/70 ,  C07H021/04 ,  C12Q001/48 ,  G01N033/53 ,  A61K038/16

    CPC分类号： A61K38/13 ,  A61K48/00

    摘要： The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.

    摘要翻译： 本发明涉及旨在靶向HBx介导的Src激酶活化，Src酪氨酸激酶家族成员和用于治疗HBV感染和相关疾病和疾病的Src激酶家族信号转导途径的组分的治疗方案和药物组合物，例如 作为HCC。 本发明还涉及用于治疗靶向HBx的HBV感染的药物组合物及其维持HBV复制所需的基本活性。 本发明部分地基于申请人的发现，即Src激酶信号级联的激活在哺乳动物肝炎病毒复制中起基础作用。 申请人已经证明HBx介导Src激酶的激活，并且这种激活是由HBx为哺乳动物肝炎病毒复制提供的关键功能。

    Substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and a medicament comprising them
    9.
    发明申请
    Substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and a medicament comprising them 失效
    取代的降冰片基氨基衍生物，其制备方法，它们作为药物或诊断剂的用途，以及包含它们的药物

    公开(公告)号：US20010023257A1

    公开(公告)日：2001-09-20

    申请号：US09734008

    申请日：2000-12-12

    发明人： Uwe Heinelt ,  Hans-Jochen Lang ,  Heinz-Werner Kleemann ,  Jan-Robert Schwark ,  Klaus Wirth ,  Hans-Willi Jansen

    IPC分类号： A61K031/275 ,  A61K031/24 ,  A61K031/135 ,  C07D317/70 ,  C07C211/00 ,  C07C255/00 ,  C07C229/00

    CPC分类号： C07C317/32 ,  C07B2200/07 ,  C07C211/38 ,  C07C211/49 ,  C07C215/30 ,  C07C217/58 ,  C07C217/60 ,  C07C217/62 ,  C07C229/38 ,  C07C237/30 ,  C07C255/58 ,  C07C257/18 ,  C07C311/37 ,  C07C323/32 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2603/68

    摘要： The application discloses substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics and a medicament comprising them Substituted norbornylamino derivatives having exo-configured nitrogen and an endo-fused five-membered ring of the formula I, or having exo-configured nitrogen and an exo-fused five-membered ring of the formula I a 1 in which R1, R2, R3, R4, R5, A, B, S1, and S2 are as defined in the claims, are highly suitable for use as antihypertensive agents, for reducing or preventing ischemically induced damage, for use as medicaments for surgical interventions for the treatment of ischemias of the nervous system, of stroke and cerebral edema, of shock, of impaired respiratory drive, for the treatment of snoring, as laxatives, as agents against ectoparasites, for the prevention of the formation of biliary calculus, as antiatherosclerotics, as agents against late diabetic complications, carcinomatous disorders, fibrotic disorders, endothelial dysfunction, and organ hypertrophies and hyperplasias. They are inhibitors of the cellular sodium/proton antiporter. They have an influence on serum lipoproteins and can therefore be used for the prophylaxis and regression of atherosclerotic changes.

    摘要翻译： 该申请公开了取代的降冰片烷基氨基衍生物，其制备方法，它们作为药物或诊断剂的用途以及包含它们的药物取代的具有外部构型的氮的降冰片基氨基衍生物和式I的内部稠合的五元环，或具有外部配置 氮和式Ib的外稠合五元环，其中R 1，R 2，R 3，R 4，R 5，A，B，S 1和S 2如权利要求中所定义，其高度适合用作抗高血压剂 ，用于减少或预防缺血性损伤，用作用于治疗神经系统缺血，中风和脑水肿，休克，呼吸驱动受损的手术干预的药物，用于治疗打鼾，作为泻药，如 用于预防胆汁结石形成的药物，作为抗动脉粥样硬化剂，作为抗晚期糖尿病并发症的药物，癌性病症，纤维化病症， 内皮功能障碍，器官肥厚和增生。 它们是细胞钠/质子逆转录酶的抑制剂。 它们对血清脂蛋白有影响，因此可用于预防和消除动脉粥样硬化变化。

    New treatment using venlafaxine
    10.
    发明申请
    New treatment using venlafaxine 失效
    使用文拉法辛的新疗法

    公开(公告)号：US20010012855A1

    公开(公告)日：2001-08-09

    申请号：US09769998

    申请日：2001-01-25

    发明人： Richard L. Rudolph ,  Albert T. Derivan ,  Eric A. Muth ,  G. Virginia Upton

    IPC分类号： A61K031/36 ,  A61K031/275 ,  A61K031/135

    CPC分类号： A61K31/137 ,  A61K31/135

    摘要： This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: 1 in which A is a moiety of the formula 2 where the dotted line represents optional unsaturation; R1 is hydrogen or alkyl; R2 is alkyl; R4 is hydrogen, alkyl, formyl, or alkanol; R5 and R6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明提供一种治疗肥胖症，广泛性焦虑症，创伤后应激障碍，晚黄体期无症状（经前期综合征），注意缺陷障碍，伴有和不伴有多动症的方法，Gilles de la Tourette综合征，神经性贪食症或Shy Drager综合征 在哺乳动物中通过向哺乳动物施用有效量的以下结构式的羟基环烷基苯乙胺：其中A是下式的部分，其中虚线表示任选的不饱和度; R1是氢或烷基; R2是烷基; R4是氢，烷基，甲酰基或烷醇; R 5和R 6独立地是氢，羟基，烷基，烷氧基，烷酰氧基，氰基，硝基，烷基巯基，氨基，烷基氨基，二烷基氨基，烷酰氨基，卤素，三氟甲基或一起，亚甲基二氧基; R7是氢或烷基; 且n为0,1,2,3或4; 或其药学上可接受的盐。